



## Metabolic Surgery Update

### Patients selection and choice of procedure

Professor John B Dixon MBBS, FRACGP, FRCP Edin, PhD  
NHMRC Senior Research Fellow  
Head of Clinical Obesity Research, Baker IDI Heart and Diabetes Institute  
Adjunct Professor – School of Primary Health Care, Monash University



### Disclosures: Professor John B Dixon

Apollo Endosurgery	Consultant, Research Support
Bariatric Advantage	Consultant, Speakers
BUPA	Research Support
Dendrite Clinical Systems	Speaker fees
I-Nova	Consultancy, Speaker and educational material
Medtronic	Speaker fees and consultancy
Nestle Health Science	Consultant
NHMRC	Research Support
Nova Nordisk	Advisory board and speaker fees
Novartis	Advisory board
Novartis	Advisory board
RACGP	Research Support


Page 2: Baker IDI

## Metabolic surgery v traditional Bariatric surgery

- Metabolic surgery – GI surgery designed with the intent to treat type 2 diabetes and obesity
- It requires a diabetes based model of clinical practice consistent with international standards of diabetes care
- Surgery should be performed in high volume centres that understand and are experienced in the management of diabetes and GI surgery
- Standard procedures should be used

Diabetes Care 2016;39: 861–877

## Accepted conventional techniques




This has always been a clear message from non-surgeons

All have their own risks and benefits

There are now multiple new "diabetes" procedures, however in Australia we appear to be largely followers not leaders in new self-styled variants

Diabetes Care 2016;39: 861–877


## BMI trends in Australian adults



2013 Adult Obesity **28%**

2025

<https://theconversation.edu.au/mapping-australias-collective-weight-gain-7816>  
Walls & Magliano et al, Obesity 2011





Global & Regional Obesity

High income English speaking

Global & Regional Severe obesity




Page 6: Baker IDI




## Let's look at those with diabetes in Australia

Page 9: Baker IDI

Baker IDI



## The compounding stressors of severe obesity in patients with diabetes



Along with obesity related disease this presents complex management issues

Dixon et al, DRCP 2013



Page 13: Baker ID


## SO WHY DO WE NEED SURGERY TO PROVIDE SUSTAINED WEIGHT LOSS AND TREAT OBESITY RELATED COMPLICATIONS LIKE TYPE 2 DIABETES?

Page 14: Baker ID



## Every essential for a functional life must be carefully regulated

- Temperature
- Oxygen saturation
- Blood pressure
- Blood glucose
- Fuel stores




The regulation of energy stores is still working when an obese patient has lost weight following bariatric surgery



Page 15: Baker ID

## Dose response curve "A change in regulation"




Page 16: Baker ID

Per Carel Le Roux



Look at the groups that did not get effective therapy – Diet & Exercise and a placebo therapy




Average weigh for participants is approximately 100kg









Page 17: Baker ID

## Obesity Treatment Pyramid




Page 18: Baker ID





## HbA1c LAGB 73% v 13% remission



Dixon, J. B., P. E. O'Brien, et al. (2008). "Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial." *Jama*, 299(3): 316-323.

Page 25: Baker ID



## When should Metabolic Surgery be performed?

- The indications for surgery have two levels of eligibility
- Surgery is an option for this patient
- Surgery is recommended for this patient**
- In the second case a trained caring physician should alert the patients to the recommendation and refer if and when appropriate

Page 26: Baker ID



## The classification of weight category by BMI

All countries use BMI criteria in their criteria for B - D surgery

Classification	BMI(kg/m <sup>2</sup> )	
	Principal cut-off points	Cut-off points for Asians
Normal range	18.5 - 24.9	18.5 - 22.9
Pre-obese	25.0 - 29.9	25.0 - 27.4
Obese class I	30.0 - 34.9	30.0 - 32.4
Obese class II	35.0 - 39.9	32.5 - 34.9
Obese class III	≥40.0	35.0 - 37.4
		37.5 - 39.9
		≥40.0

For Asian populations classifications remain the same as the international classification but that public health action points for interventions are set at 23, 27.5, 32.5 and 37.5

We address eligibility and prioritization for bariatric surgery within the coloured zones above

Source: Adapted from WHO 2004<sup>22</sup>. **BMI is an excellent measure of fatness**

Bariatric Surgical and Procedural Interventions in the Treatment of Obese Patients with Type 2 Diabetes

Page 27: Baker ID



India  
China  
Singapore  
Taiwan  
& others have adapted

## Eligibility and prioritisation for bariatric surgery based on failed non-surgical weight loss therapy, BMI, ethnicity and disease control

BMI Range	Eligible for surgery	Prioritised for Surgery
< 30	No	No
30 –35	YES-Conditional*	No
35–40	YES	YES-Conditional*
> 40	YES	YES

\*HbA<sub>1c</sub> > 7.5 despite fully optimised conventional therapy, especially if weight is increasing, or other weight responsive comorbidities not achieving targets on conventional therapies (e.g. blood pressure, dyslipidaemia, obstructive sleep apnoea)

IDF- Bariatric Surgical and Procedural Interventions in the Treatment of Obese Patients with Type 2 Diabetes

Page 28: Baker ID



## National and international guidelines for eligibility for bariatric surgery (adults)

	NIH (USA)	European	ADA (USA)	SIGN (Scotland)	NHMRC (Australia)	NICE (UK)
Year	1991	2007	2010	2010	2013	2014
Recommended						>50
Eligible (A)-BMI	>40	>40	>40		>40	>40
Eligible (B)-BMI	35 - 40 with 1 serious weight loss responsive comorbidity	35 - 40 with 1 weight loss responsive comorbidity	35-40 if control of diabetes and comorbidity is difficult	>35 with 1 serious weight loss responsive comorbidity	35 - 40 with 1 serious weight loss responsive comorbidity	35-40 with disease that could improve with weight loss
	Historic				30 - 35 If Diabetes is poorly controlled	30 - 35 If Diabetes is poorly controlled Within 10 years of diagnosis

The guidelines above are qualified by the following common elements:  
Appropriate non-surgical weight loss measures have been tried and failed; there is the provision for, and a commitment to, long term follow-up; and individual risk to benefit ratio needs to be evaluated

Page 29: Baker ID



## DSS II

Table 1—International societies that have ratified and/or endorsed the DSS-II consensus statements and guidelines

Partner diabetes organizations that helped develop and have ratified the DSS-II consensus statements and guidelines:	Country
American Diabetes Association (ADA)	USA
International Diabetes Federation (IDF)	International
Diabetes UK (DUK)	UK
Chinese Diabetes Society (CDS)	China
Diabetes India (DI)	India

Other organisations that formally endorse the DSS-II consensus statements and guidelines (the date)	Country
American Association of Clinical Endocrinologists (AACE)	USA
American College of Surgeons (ACS)	USA
American Gastroenterological Association (AGA)	USA
American Society for Metabolic and Bariatric Surgery (ASMBS)	USA
Argentine Society of Diabetes (ASD)	Argentina
Argentine Society for Bariatric and Metabolic Surgery (ASBMS)	Argentina
Asia-Pacific Bariatric and Metabolic Surgery Society (APBMSS)	International
Association of British Clinical Diabetologists (ABCD)	UK
Australian Diabetes Society (ADS)	Australia
Belgian Diabetes Association (BDA)	Belgium
Brazilian Society of Diabetes (BDS)	Brazil
Brazilian Society of Bariatric and Metabolic Surgery (BSBMS)	Brazil
British Obesity and Metabolic Surgery Society (BOMSS)	UK
Czech Society for the Study of Obesity (CSOS)	Czech Republic
Chinese Society of Endocrinology and Diabetes (CSED)	China
Chinese Society for Bariatric and Metabolic Surgery (CSBMS)	China
Endocrine Society	USA
European Association for the Study of Obesity (EASO)	International
French Society of Diabetes (SFD)	France
French Society of Bariatric and Metabolic Surgery (FSBMS)	France
German Diabetes Society (DDG)	Germany
German Society for Obesity Surgery (GA-ASBP)	Germany
Hellenic Diabetes Association (HDA)	Greece
International Federation for the Surgery of Obesity & Metabolic Disorders (IFSO)	International
Israel Diabetes Association (IDA)	Israel
Italian Society of Bariatric & Metabolic Surgery (ISCOMB)	Italy
Italian Society of Diabetology (SID)	Italy
Japan Diabetes Society (JDS)	Japan
Latin American Association of Diabetes (LAAS)	International
Mexican College of Bariatric and Metabolic Surgery (MCMBS)	Mexico
Mexican Society of Nutrition and Endocrinology (SMNE)	Mexico
Qatar Diabetes Association (QDA)	Qatar
Saudi Diabetes and Endocrine Association (SDSEA)	Saudi Arabia
Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)	USA
Society for Endocrinology (SfE)	UK
Society for Surgery of the Alimentary Tract (SSAT)	USA
South African Society for Surgery, Obesity and Metabolism (SASSO)	South Africa
Spanish Society for Bariatric and Metabolic Surgery (SSBMS)	Spain
Spanish Society of Diabetology (SSD)	Spain
The Obesity Society (TOS)	USA


This table indicates the societies that, at the time this article went to press, had officially ratified and/or endorsed the DSS-II consensus statements and guidelines. Additional international medical and scientific societies are currently considering endorsing these results as well.

Page 30: Baker ID

Diabetes Care 2016;39: 861-877




## Algorithm for the treatment of T2D, as recommended by DSS-II voting delegates



Page 33: Baker ID



## Accepted conventional techniques



This has always been a clear message from non-surgeons

All have their own risks and benefits

There are now multiple new "diabetes" procedures, however in Australia we appear to be largely followers not leaders in new self-styled variants

Diabetes Care 2016;39: 861-877



	Roux-en-Y gastric bypass	Laparoscopic adjustable gastric band	Biliopancreatic diversion with or without duodenal switch	Sleeve gastrectomy
Mean weight loss (%)	25-35%	20-30%	30-40%	20-30%
Excess weight <sup>1</sup> loss at 3-5 years <sup>1,2,3,4</sup> (%)	60% (75% with banded bypass)	50%	75%	50-60% (few reports at >3 years)
30 day postoperative mortality <sup>1,2,3,4</sup> (%)	0.3-0.5%	0.05-0.1%	0.75-1.0%	0.4%
Major 30 day morbidity <sup>1,2,3,4</sup> (%)	Laparoscopic 4-8%, open 7-8%	1%	No data available	No data available
Morbidity at 1 year <sup>1,2,3,4</sup> (%)	14-9%	4-6%	25-6%	10-8%
Pattern of weight loss <sup>1,2,3,4</sup>	Rapid, maximum at 1-2 years, weight regain at 3-5 years	Gradual, usually maximum at 2-3 years	Rapid, maximum at 1-2 years	Rapid, maximum at 1-2 years
Long-term data available <sup>1,2,3,4</sup>	Yes	Yes	Yes	No
Evidence of improved survival <sup>1,2,3,4</sup>	Yes	Yes	No	No
Nutritional concerns	Moderate deficiencies in iron, vitamin B12, folate, calcium, vitamins D, copper, zinc, and zinc	Low deficiencies in iron, vitamin B12, folate, calcium, vitamins D, copper, zinc, and zinc	High deficiencies in iron, vitamin B12, folate, calcium, vitamin D, copper, zinc, and fat-soluble vitamins	Moderate deficiencies in iron, vitamin B12, folate, calcium, vitamin D, copper, and zinc
Follow-up requirements	Lifelong assessment and nutritional support	Lifelong (high in the first 12 months) band adjustments	Lifelong assessment and nutritional support	Lifelong assessment and nutritional support
Key complications	Abdominal pain, staple-line leak, stomach ulcer, intestinal obstruction, gallstones, nutritional deficiency, weight regain	Gastric pouch dilation, erosion of band into the stomach, leaks to the gastric-band system, weight regain	Abdominal pain, staple-line leak, stomach ulcer, intestinal obstruction, gallstones, nutritional deficiency, weight regain, malabsorption, hypoburimiaemia, excessive fat malabsorption, progressive liver damage, renal calculus	Staple-line leak, gastro-oesophageal reflux disease, dilation of the gastric remnant, nutritional deficiency, weight regain

Page 36: Baker ID

Dixon, J.B., C.W. le Roux, F. Rubino and P. Zimmet, *Bariatric surgery for type 2 diabetes. Lancet, (2012), 379(9833): p. 2300-11.*



## Surgery is impressive and benefits extend well beyond a glucocentric approach


- Reduced mortality
  - Cardiovascular
  - Cancer
  - Diabetes
- Improved QOL in both physical and mental domains
- Improvement or remission of all obesity related complications
- Highly cost effective especially for diabetes

Page 38: Baker ID



## Obesity Is Linked to a Large Number of Serious Medical Conditions

### Obesity-related Co-morbidities<sup>1</sup>



MONASH University  
Obesity Research Unit  
School of Clinical Medicine, Monash Health

Bhoyrul, J Manag Care Med. 2008



## Who responds well?


Page 41: Baker ID



## Key determinants of diabetes remission

Gastric bypass  
65% remission

- Duration of Diabetes
  - Adequate beta-cell function
- Fasting C-peptide
  - Insulin resistant and adequate beta-cell function
- BMI
  - You must have weight to lose
- (% Weight Loss)
  - You must lose weight



Page 42: Baker ID

Dixon, J.B., Lee W.J. et al Diabetes Care (2013)

## SOS study - IDF Melbourne 2013


- 31% still in remission at 15 years
- Diabetes complications cases v controls
  - Adjusted OR 0.53 (0.37 – 0.76)
- Those with diabetes that had a reduction in micro & macrovascular complications are treated within 3 years of a diagnosis of type 2 diabetes

Peltonen et al, Diabetes remission and complications over 15 years in SOS study IDF 2013

Page 44: Baker ID



## Chronic Care Management Model



Page 45: Baker ID



## The serial accumulation of impressive data

- 2006 Data from 4 studies indicating that bariatric surgery saves lives – Cardiovascular, Diabetes, Cancer.
- The evidence that the risks of surgery have plummeted with the laparoscopic approach and quality training – the technology used in surgery has been revolutionised
- Risk less than gall bladder surgery – No deaths in UK last year.
- The durability of weight loss – SOS and many more
- The 11 randomized controlled trials
- Health economic data – highly cost effective and for those with type 2 diabetes possibly dominant
- Change underway, but the systems to implement the needed changes are not established

Page 46: Baker ID




## Conclusion

- Chronic disease management is integrated health not “medicine v surgery”
- Surgery compliments conventional therapy
- Endocrinologists and diabetologists need to engage bariatric-metabolic surgical teams to assist with the management of their numerous patients who are eligible or prioritized for surgery
- We have done this oncology, other endocrine disorders, cardiology – **Why not Bariatric-Metabolic surgery?**

Page 47: Baker ID



## Division of Hypertension, Obesity and Stress Clinical Obesity Research



Page 48: Baker ID

